-
Mideast war threatens energy crisis worse than 1970s oil shocks
-
Pilot, co-pilot killed in runway collision at New York airport
-
Plane, fire truck collide on runway at New York's LaGuardia Airport
-
Russia's Max: The unencrypted super-app being forced on citizens
-
EU chief in Australia with eyes on trade deal
-
Asia champions Japan need 'different tools' to win World Cup - coach
-
Global economy under 'major threat' from Strait of Hormuz crisis: IEA chief
-
Planet trapped record heat in 2025: UN
-
Israel launches new strikes on Tehran as Iran takes aim at Gulf sites
-
German court to rule in climate case against automakers
-
France's leftists win mayoral elections in largest cities
-
Asian stocks tumble as Trump gives Iran 48-hour ultimatum
-
Wolves rally past Celtics, Nuggets sink Blazers
-
Middle East war to dominate Houston's 'Davos of Energy'
-
Kim holds off Korda charge to win LPGA Founders Cup
-
Trump orders immigration agents to airports amid crippling budget standoff
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - March 23
-
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
-
ABRIDGED, PRELIMINARY AND UNAUDITED QUARTERLY AND FULL YEAR RESULTS AND DETAILS OF MANAGEMENT CONFERENCE Call for the Fourth Quarter and Full Year Ended December 31, 2025 ("The Quarter" or "Q4 2025" and "FY 2025" Respectively)
-
Iran awaits Trump threat to blow up power plants
-
Alcaraz eyes clay court season after early Miami exit
-
Real Madrid down Atletico in derby, leaders Barca edge Rayo
-
Korda sends Alcaraz to another early exit in Miami
-
Bordeaux-Begles hammer Toulouse in Dupont absence
-
Slovenia PM claims election win as results show neck and neck finish
-
England's Fitzpatrick birdies 18th to win PGA Valspar title
-
Man City's League Cup glory adds twist to title race
-
Leftists win mayoral elections in Paris and Marseille
-
Vinicius double helps Real Madrid edge Atletico thriller
-
Doncic cleared to face Pistons after foul rescinded: NBA
-
Inter's Serie A lead cut to six with Fiorentina draw, Como march on
-
World No.1 Alcaraz beaten by Korda in Miami Open third round
-
Cuba starts to restore power after new blackout
-
Ovechkin nets 1,000th combined NHL season-playoffs goal
-
Undav doubles up as Stuttgart down Augsburg to go third
-
Leftists win mayoral elections in Paris and Marseille: projections
-
Israel warns weeks of fighting ahead in Mideast war
-
Guardiola revels in Man City's 'special' League Cup win over Arsenal
-
Hodgkinson headlines Britain's 'Super Sunday' at world indoors
-
Messi scores for Miami in 3-2 MLS victory at NYCFC
-
Bezzecchi wins second race of the season at Brazil MotoGP
-
Britain's Hodgkinson wins world indoor 800m gold
-
Former France and West Ham star Payet announces retirement
-
Man City's O'Reilly savours 'unbelievable' double in League Cup final win
-
Israel to advance ground operations in Lebanon after striking key bridge
-
Man City win League Cup as O'Reilly sinks Arsenal after Kepa blunder
-
Marseille downed by Lille in Ligue 1 as Lyon's struggles continue
-
NBA bans Mitchell, Champagnie one game for sparking melee
-
'Project Hail Mary' rockets to top of N. America box office
-
Syrians protest alcohol sale limits, curbs on personal freedom
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
CAMBRIDGE, MA, MA / ACCESS Newswire / October 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025 to report its third quarter 2025 financial results, and provide a corporate update.
A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.
Webcast: https://investors.modernatx.com
The archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Media Contacts
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
[email protected]
SOURCE: Moderna, Inc.
View the original press release on ACCESS Newswire
P.Mathewson--AMWN